Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate

Trial Profile

Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms Double-ITK-GVHc
  • Most Recent Events

    • 24 Aug 2017 Planned End Date changed from 1 Mar 2023 to 1 Mar 2018.
    • 24 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 01 Sep 2016 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top